BI 764532 Dose Tolerance Study in DLL3-Positive Brain Tumor Patients Initiated
A clinical trial is underway to evaluate the tolerability of BI 764532 in adults with DLL3-positive brain tumors.
Asset / Drug
Drug and asset intelligence for BI with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
CD3 Bispecific Antibody
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.